Ann: Appendix 3Y-Dr Geoffrey Brooke, page-28

First 28 Last

Share
Profile

Follow
gavint66

3,938 Posts.

287

21/05/24

19:36

Post #: 73941417
Share

Originally posted by bedger: ↑

I and others on here are consumately acquainted with the timescales involved in bio-tech investments Pledge, thanks for your concerns over me or others being unaware of CYP's as yet uncompleted pathway to actual commercial success. Why I personally have been not been invested in both MSB and CYP for the vast majority of their listed history since 2004 and 2007 respectively, along with the share prices.

Its about the entry levels Pledge and the trading prices of CYP is now well above my buy average, and MSB for that matter, whilst both are a long way from the eventual commercial success we are all ultimately investing in. For abnormal returns on both investments I don't personally (nor many others reading) need either to be actually in market selling treatments commercially, just the market to be aware they soon will be and forward valued accordingly.

(I can almost hear you laud MSB's recent and hopefully pending progress with the FDA over CYP holders - suits me as an investor in both (and arguably CYP investors who are not invested in MSB) - when its only a few years ahead of CYP which itself might have similarly progressed levels to that of MSB i.e. it too 20 years after its IPO might finally be sniffing at approvals )

Expand

A few years ahead ? Brahahahahhah

CYP Price at posting: 27.5¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

There are more pages in this discussion • 14 more messages in this thread...

First 28 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 25.0¢		Change -0.010(3.85%)		Mkt cap ! $44.90M

Open	High	Low	Value	Volume
26.0¢	26.5¢	25.0¢	$5.869K	22.42K

Buyers (Bids)

No.	Vol.	Price($)
1	29342	25.0¢

Sellers (Offers)

Price($)	Vol.	No.
27.0¢	30000	1

View Market Depth

No.	Vol.	Price($)
1	29342	0.250
2	31297	0.245
4	107225	0.240
1	100000	0.235
2	15173	0.230

Price($)	Vol.	No.
0.270	30000	1
0.290	7125	3
0.295	183892	1
0.300	85000	2
0.310	16591	3

Last trade - 15.47pm 11/07/2024 (20 minute delay)

CYP (ASX) Chart

Ann: Appendix 3Y-Dr Geoffrey Brooke, page-28

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Canadian fieldwork yields multiple pegmatites for Trinex

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 3Y-Dr Geoffrey Brooke, page-28

Top Stories

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Canadian fieldwork yields multiple pegmatites for Trinex

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News